Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

被引:5
|
作者
Ando, Yukio [1 ]
Waddington-Cruz, Marcia [2 ]
Sekijima, Yoshiki [3 ]
Koike, Haruki [4 ,5 ]
Ueda, Mitsuharu [6 ]
Konishi, Hiroaki [7 ]
Ishii, Tomonori [7 ]
Coelho, Teresa [8 ]
机构
[1] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Amyloidosis Res, 2825-7 Huis Ten Bosch Sasebo, Sasebo, Nagasaki 8593298, Japan
[2] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Estudos Paramiloidose Antonio Rodrigues Mello, Rio De Janeiro, RJ, Brazil
[3] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Japan
[4] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Japan
[5] Saga Univ, Fac Med, Dept Internal Med, Div Neurol, Saga, Japan
[6] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[7] Pfizer Japan Inc, Tokyo, Japan
[8] Ctr Hosp Univ Porto, Hosp Santo Antonio, Andrades Ctr Familial Amyloidosis, Porto, Portugal
关键词
Asymptomatic; ATTR amyloidosis; Biopsy; Cardiomyopathy; Gene mutation carrier; Genetic counseling; Neuropathy; Noninvasive testing; Practical guidance; Predictive genetic testing; CARPAL-TUNNEL-SYNDROME; DIAGNOSTIC-ACCURACY; POLYNEUROPATHY; SYMPTOM; ONSET; PROGRESSION; PREVALENCE; TAFAMIDIS; CONSENSUS; FOCUS;
D O I
10.1186/s13023-023-02910-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients' genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients' nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data
    Mueller, Maximilian Leo
    Latinova, Ekaterina
    Brand, Anna
    Mattig, Isabel
    Spethmann, Sebastian
    Messroghli, Daniel
    Hahn, Katrin
    Landmesser, Ulf
    Heidecker, Bettina
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (14):
  • [42] Real-World Outcomes In Hereditary Angioedema: Experience From The Icatibant Outcome Survey In The United Kingdom
    Longhurst, Hilary
    Dempster, John
    Lorenzo, Lorena
    Buckland, Matthew
    Grigoriadou, Sofia
    Fabien, Vincent
    Bangs, Catherine
    Helbert, Matthew
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 10 - 11
  • [43] Genotype vs phenotype and access to treatment in patients with hereditary transthyretin amyloidosis from a reference center in Brazil
    de Souza, Fabio
    Bittar-Braune, Caroline
    Fernandes da Silva, Yuri Vianna
    Foureaux, Matheus Medeiros
    Correa Filho, Wilson Braz
    Porto, Sebastiana Bessa
    Simoes, Kelma
    Franz, Cibele
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S26 - S27
  • [44] A Real-World Overview of Diabetes Mellitus Profile and Management in Brazil
    Chacra, Antonio R.
    Franco, Denise R.
    Calliari, Luis E. P.
    Eliaschewitz, Freddy G.
    Ferreira, Graziela
    Paula, Mauricio A.
    Lima, Leila
    Lauand, Felipe
    DIABETES, 2017, 66 : A653 - A653
  • [45] Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
    Magi, Ludovica
    Mazzuca, Federica
    Rinzivillo, Maria
    Arrivi, Giulia
    Pilozzi, Emanuela
    Prosperi, Daniela
    Iannicelli, Elsa
    Mercantini, Paolo
    Rossi, Michele
    Pizzichini, Patrizia
    Laghi, Andrea
    Signore, Alberto
    Marchetti, Paolo
    Annibale, Bruno
    Panzuto, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [46] The Journey to Diagnosis of Light Chain Amyloidosis: A Real-World Experience from a Single Center in Latin America
    Oses, Lucrecia
    Carretero, Marcelina
    Brulc, Erika
    Posadas, Maria
    Nucifora, Elsa
    Schutz, Natalia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S211 - S211
  • [47] The Journey to Diagnosis of Light Chain Amyloidosis: A Real-World Experience from a Single Center in Latin America
    Liliana Oses, Lucrecia
    Carretero, Marcelina
    Lourdes Posadas, Maria
    Barbara Brulc, Erika
    Mercedes Nucifora, Elsa
    Paola Schutz, Natalia
    BLOOD, 2023, 142
  • [48] Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan
    Taro Yamashita
    Mitsuharu Ueda
    Yohei Misumi
    Teruaki Masuda
    Toshiya Nomura
    Masayoshi Tasaki
    Kotaro Takamatsu
    Keiko Sasada
    Konen Obayashi
    Hirotaka Matsui
    Yukio Ando
    Journal of Neurology, 2018, 265 : 134 - 140
  • [49] Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches
    Daniel Serrano
    Christopher B. Atzinger
    Marc F. Botteman
    Neurology and Therapy, 2018, 7 : 141 - 154
  • [50] Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan
    Yamashita, Taro
    Ueda, Mitsuharu
    Misumi, Yohei
    Masuda, Teruaki
    Nomura, Toshiya
    Tasaki, Masayoshi
    Takamatsu, Kotaro
    Sasada, Keiko
    Obayashi, Konen
    Matsui, Hirotaka
    Ando, Yukio
    JOURNAL OF NEUROLOGY, 2018, 265 (01) : 134 - 140